Display options
Cite
Bergmann S, Curzon G, Friedel J, et al. The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism. Br J Clin Pharmacol. 1974;1(5):417-24doi: 10.1111/j.1365-2125.1974.tb00280.x.
Bergmann, S., Curzon, G., Friedel, J., Godwin-Austen, R. B., Marsden, C. D., & Parkes, J. D. (1974). The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism. British journal of clinical pharmacology, 1(5), 417-24. https://doi.org/10.1111/j.1365-2125.1974.tb00280.x
Bergmann, S, et al. "The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism." British journal of clinical pharmacology vol. 1,5 (1974): 417-24. doi: https://doi.org/10.1111/j.1365-2125.1974.tb00280.x
Bergmann S, Curzon G, Friedel J, Godwin-Austen RB, Marsden CD, Parkes JD. The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism. Br J Clin Pharmacol. 1974 Oct;1(5):417-24. doi: 10.1111/j.1365-2125.1974.tb00280.x. PMID: 22454921; PMCID: PMC1402477.
Copy Download .nbib Format: NLM
Share it on

Br J Clin Pharmacol. 1974 Oct;1(5):417-24. doi: 10.1111/j.1365-2125.1974.tb00280.x.

The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.

British journal of clinical pharmacology

S Bergmann, G Curzon, J Friedel, R B Godwin-Austen, C D Marsden, J D Parkes

Affiliations

  1. National Hospital, Queen Square, London.

PMID: 22454921 PMCID: PMC1402477 DOI: 10.1111/j.1365-2125.1974.tb00280.x

Abstract

1 The metabolism of a standard oral dose of levodopa was studied in forty-two patients with Parkinsonism. Plasma levodopa and 3-o-methyldopa concentrations were estimated at intervals for 8 h after ingestion and the concentration of homovanillic acid (HVA) in the lumbar cerebrospinal fluid (CSF) was measured at 8 hours. Clinical responses 3 months after the test were compared with these findings. 2 Although therapeutic benefit correlated significantly with calculated estimates of both plasma levodopa concentration and CSF HVA at optimal levodopa dose, individual values were widely scattered. There was no significant correlation between toxic effects and plasma levodopa or CSF HVA; and 3-o-methyldopa concentrations similarly did not show a significant correlation with either toxic or therapeutic effects. 3 Blood and CSF levels of levodopa or the metabolites measured in this study were not significantly altered by concurrent treatment with either anticholinergic drugs or amantadine nor by previous treatment with levodopa.

References

  1. J Neurol Neurosurg Psychiatry. 1970 Apr;33(2):269-72 - PubMed
  2. J Neurol Neurosurg Psychiatry. 1970 Feb;33(1):1-6 - PubMed
  3. Br Med J. 1970 Oct 10;4(5727):93-4 - PubMed
  4. Lancet. 1971 Feb 20;1(7695):395 - PubMed
  5. Wien Klin Wochenschr. 1961 Nov 10;73:787-8 - PubMed
  6. Can Med Assoc J. 1962 Oct 13;87:802-7 - PubMed
  7. J Neurol Neurosurg Psychiatry. 1970 Dec;33(6):851-7 - PubMed
  8. Br Med Bull. 1973 May;29(2):172-8 - PubMed
  9. Eur J Pharmacol. 1970 May;10(2):189-92 - PubMed
  10. Proc Natl Acad Sci U S A. 1971 Mar;68(3):662-6 - PubMed
  11. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):212-7 - PubMed
  12. Br Med J. 1973 Jun 16;2(5867):641-3 - PubMed
  13. Clin Pharmacol Ther. 1973 May-Jun;14(3):386-9 - PubMed
  14. Clin Chim Acta. 1972 Mar;37:335-41 - PubMed

Publication Types